摘要
目的探讨冠心病患者血清铁调素(Hepc)、心肌肌钙蛋白I(cTnI)和同型半胱氨酸(Hcy)检测的临床意义。方法选取冠心病患者120例(冠心病组),其中稳定型心绞痛(SAP)患者40例、不稳定型心绞痛(UAP)患者40例、急性心肌梗死(AMI)患者40例。另选取同期体检健康者40名作为正常对照组。采用酶联免疫吸附试验(ELISA)检测Hepc,化学发光法检测cTnI,循环酶法检测Hcy。结果冠心病组血清Hepc、cTnI、Hcy水平分别为94.3(36.3~134.6)μg/L、0.180(0.017~0.490)μg/L、(19.3±7.7)μmol/L,均高于正常对照组(P<0.05)。Hepc、cTnI、Hcy水平SAP组>UAP组>AMI组(P<0.05)。SAP组Hepc水平[67.9(33.7~74.5)μg/L]明显高于正常对照组[31.6(26.8~39.7)μg/L](P<0.05)。Hepc、cTnI、Hcy诊断冠心病受试者工作特征(ROC)曲线的曲线下面积(AUC)分别为0.932、0.841、0.812,Hepc诊断冠心病的最佳临界值为36.8μg/L,敏感性为85.3%,特异性为98.3%。结论Hepc、cTnI、Hcy均可作为冠心病的诊断指标,Hepc具有最大的诊断价值。
Objective To investigate the roles of serum hepcidin(Hepc),cardiac troponin I(cTnI)and homocysteine(Hcy)in patients with coronary heart disease.Methods A total of 120 patients with coronary heart disease were enrolled.There were 40 cases of stable angina pectoris(SAP),40 cases of unstable angina pectoris(UAP)and 40 cases of acute myocardial infarction(AMI).A total of 40 healthy subjects were enrolled as healthy control group.The level of Hepc was determined by enzyme-linked immunosorbent assay(ELISA),cTnI was determined by chemiluminescence,and Hcy was determined by enzymatic cycling assay.Results The level of Hepc in coronary heart disease group was 94.3(36.3-134.6)μg/L,cTnI was 0.180(0.017-0.490)μg/L,and Hcy was(19.3±7.7)μmol/L,which were higher than those in healthy control group(P<0.05).The levels of Hepc,cTnI and Hcy in SAP group,UAP group and AMI group were increased in turn,respectively(P<0.05).The level of Hepc was 67.9(33.7-74.5)μg/L in SAP group,which was higher than that in healthy control group[31.6(26.8-39.7)μg/L](P<0.05).The areas under receiver operating characteristic(ROC)curves(AUC)of Hepc,cTnI and Hcy in the diagnosis of coronary heart disease were 0.932,0.841 and 0.812,and the optimal cut-off value of Hepc was 36.8μg/L.The diagnostic sensitivity was 85.3%,and the diagnostic specificity was 98.3%.Conclusions Hepc,cTnI and Hcy can be used as indicators in the diagnosis of coronary heart disease,and Hepc is the indicator with good performance.
作者
舒铭
金鹿
陈秋莹
SHU Ming;JIN Lu;CHEN Qiuying(Zhoupu Hospital,Shanghai University of Medicine and Health Sciences,Shanghai 201318,China;Shanghai Pudong Mental Health Center,Shanghai 200034,China)
出处
《检验医学》
CAS
2019年第9期783-786,共4页
Laboratory Medicine
基金
上海健康医学院种子基金项目(SFP-18-22-17-008)
